Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ADCT-211
i
Other names:
ADCT-211
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Twitter
Trials
Company:
ADC Therapeutics
Drug class:
DNA replication inhibitor, IL-13Rα2-targeted antibody-drug conjugate
Related drugs:
‹
gemtuzumab ozogamicin (22)
inotuzumab ozogamicin (21)
bendamustine (12)
SYD985 (6)
SOT102 (5)
loncastuximab tesirine (5)
MGC018 (4)
rovalpituzumab tesirine (3)
ADCT-301 (2)
IMGN632 (2)
ABBV-321 (2)
DHES0815A (1)
IMGN779 (1)
SGN-CD70A (1)
TR1801-ADC (1)
ADCT-601 (1)
SGN-CD33A (1)
gemtuzumab ozogamicin (22)
inotuzumab ozogamicin (21)
bendamustine (12)
SYD985 (6)
SOT102 (5)
loncastuximab tesirine (5)
MGC018 (4)
rovalpituzumab tesirine (3)
ADCT-301 (2)
IMGN632 (2)
ABBV-321 (2)
DHES0815A (1)
IMGN779 (1)
SGN-CD70A (1)
TR1801-ADC (1)
ADCT-601 (1)
SGN-CD33A (1)
›
Associations
(1)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
IL13RA2 expression
Solid Tumor
IL13RA2 expression
Solid Tumor
ADCT-211
Sensitive: D – Preclinical
AACR 2023 - 1 week (New D)
ADCT-211
Sensitive
:
D
AACR 2023 - 1wk
ADCT-211
Sensitive: D – Preclinical
AACR 2023 - 1 week
ADCT-211
Sensitive
:
D
AACR 2023 - 1 week - (New D)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login